Corgenix teams up with SpectraCell for AspirinWorks
This article was originally published in Clinica
Executive Summary
Denver, Colorado-based IVD company Corgenix has formed a partnership with Houston, Texas lab testing services firm SpectraCell, which will see the latter use Corgenix's AspirinWorks test to assess a patient's risk of an adverse cardiovascular event. AspirinWorks determines the effect of aspirin on platelets in apparently healthy individuals by measuring the level of thromboxane production (the higher the levels of thromboxane, the sticker the blood platelets and the increased likelihood of a blood clot-related cardiovascular event).